Thread by @JuliaLaiKwon

Slowly digesting #ASCO20. Lots of fantastic patient-reported outcomes #PRO work incl in #phase1 #oncology.

5 presentations that caught my attention:

1/5 eRAPID (#7002) @DrKateAbsolom @UniversityLeeds.
💡RCT of weekly #PRO reporting and self-mx vs usual care for pts on chemo.
❗️ ⬆️early sx control, self-efficacy and #QOL w/o increasing clinical workload.
❓adapt for IO/ targeted therapy, monitoring during #COVID19

2/5 Creating composite PRO-CTCAE scores (#7018) @BiostatGirl @EthanBasch1
💡Developed algorithm for composite scores for PRO-CTCAE, combining frequency, severity and interference into a single metric like CTCAE.
❗️Will aid PRO-CTCAE uptake/ interpretation in trials/ routine care

3/5 Patient + clinician attitudes to #PRO collection (#7044) @EthanBasch1 @corp_UNC
💡Qualitative study n=147 nurses, oncologists, data mx, pts.
⬆️pt awareness of sx, communication btw pts and carers, quality of care.
❓ challenges- limited consult time + nursing time to rv PROs

4/5 Mapping PRO-CTCAE responses to clinician-assessed AEs in #Phase1 trials (#2014) @z_veitch @pmcancercentre
❗️ #PRO-CTCAE severity/interference assoc with CTCAE G2/3/4 AEs, dose interruptions and discontinuations.
❓ How can we incorporate #PRO info to define tolerable doses

5/5 Using #PROs to describe sx in pts on #phase1 trials (#12107) @ramsedhom @cityofhope
💡479 pts, PRO-CTCAE @ baseline,4,12 wks
❗️Valid in Ph1, small-mod correlation with distress level and FACT-G
❗️PROs can accurately capture sx, inform tolerability of novel tx

@DrAbhiPal @udai_banerji @ChristinaBYap @staplehedge @MartinStockler @fischmd @M_Jefford @bogda_koczwara @pkluetz